Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 11;21(15):2974-2980.
doi: 10.7150/ijms.101261. eCollection 2024.

Challenging Conventional Wisdom: Early Treatment and Chronicity Outcomes in Acute Severe Hepatitis B

Dilara Turan Gökçe  1 , Derya Arı  2 , Melike Yakut  3 , Burçak Kayhan  4 , Emin Altıparmak  2 , Adalet Altunsoy  5 , Meral Akdoğan Kayhan  2
Affiliations

Challenging Conventional Wisdom: Early Treatment and Chronicity Outcomes in Acute Severe Hepatitis B

Dilara Turan Gökçe et al. Int J Med Sci. .

Abstract

This study aimed to evaluate the clinical outcomes of patients diagnosed with acute severe hepatitis B (ASHB) who received early antiviral therapy compared to those who did not. Patients diagnosed with acute hepatitis B between February 2019 and February 2023 at our hospital were retrospectively analyzed for admission characteristics, antiviral treatments, and serum HBsAg and anti-HBs levels over 3-6-12 months. Acute severe hepatitis B was defined as serum total bilirubin > 5 mg or INR > 1.5. Of the 57 patients included, 26.3% (n=15) were female, and the median age was 40.2 (21-90) years. Within 48 hours of admission, 2 patients had concurrent diseases (3%) died. Two patients with concurrent HIV diagnosis were excluded. Treatment was initiated in 27 of 53 ASHB patients (entecavir/tenofovir: 24/3). One patient in the treatment group underwent liver transplantation due to fulminant hepatitis, and another patient died while on the waiting list. Long-term follow-up information for 3 patients in the untreated group was unavailable. The study continued with 25 treated and 23 untreated patients. No significant differences were observed in age, ALT levels, albumin, leukocyte, neutrophil, and platelet levels between the two groups (respectively; p = 0.57, p = 0.071, p = 0.187, p = 0.46, p = 0.94, p = 0.307). However, in the treated group, AST, total bilirubin, INR, and hospitalization duration were higher, and lymphopenia was more common. In the entire patient population, HBsAg seroclearance rates were 54% at 3 months (69% in treated vs. 34% in untreated; p = 0.127), 83.3% at 6 months (95% in treated vs. 74% in untreated; p = 0.218), and 100% at 12 months. Early antiviral therapy did not show an association with chronicity in ASHB patients. Conducting randomized controlled studies with a larger patient population is necessary to provide a definitive conclusion on initiating early antiviral therapy. However, such studies pose ethical challenges.

Keywords: acute hepatitis B; antiviral treatment; chronicity.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
The visual chart of the patients evaluated in the study.
Figure 2
Figure 2
The percentage rate of HbsAg seroclearence (p values in order are p=0.127, p= 0.289 and NA) (created with BioRender.com).
See this image and copyright information in PMC

References

    1. Number of reported cases of acute Hepatitis B virus infection and estimated infections† — United States, 2014-2021. 2021. https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-b/fi....
    1. Republic of Turkey, Ministry of Health, General Directorate of Public Health. Turkey Viral Hepatitis Prevention and Control Program. 2018. Retrieved from. https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklar-db/duyurul....
    1. Coppola N, Sagnelli C, Pisaturo M. et al. Clinical and virological characteristics associated with severe acute hepatitis B. Clin Microbiol Infect. 2014;20(12):O991–O997. doi:10.1111/1469-0691.12720. - PubMed
    1. Pietro Lampertico, Kosh Agarwal, Thomas Berg. et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017;67:370–398. https://doi.org/10.1016/j.jhep.2017.03.021. - PubMed
    1. Terrault NA, Lok ASF, McMahon B J. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800. - PMC - PubMed

MeSH terms

LinkOut - more resources